Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Omniose Announces Expanded Leadership Team to Develop Bioconjugate Vaccines Against Serious Bacterial Threats

Latest Posts

Sonrava Health to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration with Cerebrae and Sera Prognostics

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and...

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, announced today the expansion of the leadership team to include Timothy Cooke, Ph.D., MBA as Chief Executive Officer and Roman Fleck. Ph.D., MBA as Chairperson.

Dr. Cooke has over 30 years of experience in the vaccine industry and is active in vaccine policy roles, including the Biotechnology Industry Representative to the US National Vaccine Advisory Committee and Observer to the WHO Technical Advisory Group on Vaccines and Antimicrobial Resistance. Dr. Fleck is a seasoned entrepreneur & venture investor with over 20 years of experience in the biotech industry. The research team will be led by Christian Harding, Ph.D., Chief Scientific Officer and Co-Founder of Omniose.

Omniose is also announcing the formation of its Scientific Advisory Board including Mario Feldman, Ph.D., a Co-Founder and pioneer in engineering glycoconjugate vaccines using enzymatic conjugation, Viliam Pavliak, Ph.D., who has deep industry expertise in conjugate vaccine development at Wyeth/Pfizer, and Steven Projan, Ph.D., who brings broad industry experience in infectious disease, drug and vaccine development at MedImmune, Novartis and Wyeth/Pfizer.

“Omniose combines great science with a dedicated team on a mission to protect people from serious bacterial infections,” said Timothy Cooke, CEO. “Our approach greatly expands the universe of bacterial targets that can be addressed by bioconjugate vaccines.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine